Dual Hedgehog mTOR Inhibitor Therapy for Esophageal Adenocarcinoma Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies for esophageal adenocarcinoma (EAC) are limited by resistance to Hedgehog pathway inhibitors, and there is a need for novel therapeutic targets and biomarkers for early detection and personalized treatment approaches.
Innovation Solution
The development of methods involving the use of mTOR and Hedgehog pathway inhibitors, with personalized therapy selection based on mTOR and Hedgehog signaling markers such as S6K phosphorylation and Gli1 expression levels in tumor samples, to tailor treatment strategies for esophageal tumors and Barrett's esophagus.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Hedgehow pathway inhibitors are used to treat esophageal adenocarcinoma, then tumor growth inhibition is achieved, but resistance develops reducing treatment effectiveness
Solution Approach 1:
The patent combines Hedgehow pathway inhibitors with mTOR inhibitors in a dual-pathway targeted therapy. This merging of two different therapeutic agents addresses resistance to single-pathway inhibition by simultaneously blocking both Hedgehow signaling (through SMO inhibition) and mTOR signaling, thereby overcoming adaptive resistance mechanisms and improving treatment reliability
Solution Approach 2:
The patent changes the therapeutic parameter from single-pathway inhibition to dual-pathway inhibition. By introducing a second inhibitor targeting a different signaling pathway (mTOR), the treatment parameter is expanded to address resistance, transforming the therapy from monotherapeutic to combination therapeutic approach
2Measurement precision
If personalized therapy based on multiple biomarkers is implemented, then treatment precision is improved, but diagnostic complexity increases
Solution Approach 1:
The patent segments the diagnostic process into distinct, measurable components: S6K phosphorylation status and Gli1 expression levels. Each biomarker is evaluated independently through specific detection methods, allowing complex personalized therapy selection to be broken down into manageable, discrete diagnostic steps that reduce overall system complexity
Data Source
AI summary
Methods and composition for tumor therapy, especially esophageal adenocarcinoma (EAC), are described. For example, in certain aspects methods for determining Hedgehog and mTOR signaling pathway status to select patients for administering a combination therapy of Hedgehog and mTOR signaling inhibitors are described. Furthermore, the invention provides compositions that involve testing kits for determining signaling status.